Whole-exome sequencing of genomic DNA extracted from patient-derived melanoma cell lines resistant to vemurafenib (PLX) or trametinib (TRA). Whole-exome sequencing of genomic DNA extracted from patient-derived melanoma cell lines resistant to vemurafenib (PLX) or trametinib (TRA)

Whole-exome sequencing was performed on DNA samples extracted from seven melanoma cell lines resistant to either vemurafenib (BRAF V600E inhibitor) or trametinib (MEK1/2 inhibitor). The aim of the experiment was to search for genetic alterations responsible for phenotypic diversity of melanoma cell lines reported at the level of cell morphology, activity of signaling pathways essential for melanoma development and progression, and resistance to targeted therapeutics.

本研究对从7株分别对维莫非尼（vemurafenib，BRAF V600E抑制剂）或曲美替尼（trametinib，MEK1/2抑制剂）产生耐药性的黑色素瘤细胞系中提取的DNA样本开展了全外显子组测序（Whole-exome sequencing）。本实验旨在探寻与黑色素瘤细胞系表型多样性相关的遗传变异，此类细胞系的表型多样性体现在细胞形态、黑色素瘤发生及进展所必需的信号通路活性，以及对靶向治疗药物的耐药性层面。